Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing
company focused on the development of potentially curative
therapeutics using CRISPR technology, announced today the
appointment of Moncef Slaoui, Ph.D. and Frank Verwiel, M.D. to its
Board of Directors. Drs. Slaoui and Verwiel will begin Board
responsibilities effective immediately. Intellia’s Board of
Directors also is establishing a Science and Technology Committee,
which will be chaired by Dr. Slaoui. Additionally, Carl L. Gordon,
Ph.D., CFA, General Partner, OrbiMed Advisors, LLC, has informed
the Company of his resignation from the Intellia Board of Directors
effective at that close of business on July 25, 2017.
“We are very pleased to welcome Drs. Slaoui and
Verwiel to our Board of Directors. They bring decades of
scientific, operational, business and strategic experience in the
pharmaceutical and biotech industries to Intellia. We look forward
to their guidance as we continue to advance our genome editing
technology to patients,” said Perry Karsen, Chair of the Board of
Directors, Intellia Therapeutics. “On behalf of the Board of
Directors, I want to thank Carl Gordon for his leadership in
establishing Intellia and for all of his contributions to the
Company.”
Dr. Moncef Slaoui brings more than 30 years
of experience in pharmaceutical drug research and development, new
product launches and business development to Intellia’s Board of
Directors
Dr. Moncef Slaoui recently retired as Chairman of
Vaccines at GlaxoSmithKline (GSK), where he also served on the
company’s executive team and board of directors for eleven years.
During his nearly 30-year career at GSK, he amassed significant
expertise in drug discovery and development, business development,
new product development and commercial organizations. Dr. Slaoui
led the global integration of Novartis’ vaccine unit into GSK. Dr.
Slaoui was chairman of GSK’s global R&D organization for eight
years, bringing improved productivity with more than 30 phase 3
programs, and re-organizing drug discovery to accommodate 38
focused discovery performance units in the company. Additionally,
Dr. Slaoui was responsible for GSK’s venture capital arm, SR One,
and other venture capital partnerships.
Dr. Slaoui led the company’s bioelectronics R&D
strategy, including the launch of Galvani Bioelectronics, a company
where he remains Chairman of the board of directors.
Dr. Slaoui has authored more than 100 scientific
papers and presentations and served on the board of directors for
the Pharmaceutical Research and Manufacturers of America’s
Foundation, the Biotechnology Innovation Organization’s board of
directors, and was a member of the National Institutes of Health’s
Advisory Committee until 2016. Currently, he is a member of the
Advisory Board for the Qatar Foundation.
Dr. Slaoui received his Ph.D. in Molecular Biology
and Immunology from the Université libre de Bruxelles Belgium and
completed post-doctoral studies at Harvard Medical School and Tufts
University of Medicine in Boston.
Dr. Frank Verwiel brings more than 25 years
of strategic, operational and international expertise in the
biotechnology and pharmaceutical industries and over a decade of
industry board experience
Dr. Verwiel possesses significant biotech and
pharmaceutical experience, having been the president and CEO of
Aptalis Pharma Inc., prior to its acquisition in 2014 by Forest
Laboratories. Dr. Verwiel also was a vice president at Merck &
Co., where he led the global hypertension franchise. He also served
as the general manager of Merck Sharpe Dohme’s operations in the
Netherlands. He held numerous leadership positions in the
commercial organization at Servier Laboratories.
Dr. Verwiel currently serves as chairman of the
board of directors of ObsEva SA, a biopharmaceutical company
focused on women’s reproductive health. Dr. Verwiel holds
membership and committee chair positions on the boards of AveXis,
Inc., Achillion Pharmaceuticals, Inc. and Bavarian Nordic A/S.
Previously, he served on the board of directors of Intermune, until
its acquisition by Roche in 2014, and the Biotechnology Innovation
Organization.
Dr. Verwiel received a doctorate in medicine from
Erasmus University in Rotterdam, Netherlands. He received a Masters
of Business Administration from the Institut Européen
d'Administration des Affaires (INSEAD) in Fontainebleau,
France.
New Science and Technology Committee
Supports Intellia’s R&D Strategy
In recognition of the company’s advances and
opportunities in applying the CRISPR/Cas technology platform,
Intellia’s Board of Directors is creating a new committee to the
Board, the Science and Technology Committee. This committee will
support the Board of Directors in its oversight and advisement of
the Company’s research and development activities and scientific
strategy. The Science and Technology Committee will be chaired by
Dr. Slaoui, given his extensive operational, scientific and
industry experience.
“Both Drs. Slaoui and Verwiel have served as board
directors for key organizations and were top executives at
companies that delivered innovative medicines to patients,” said
Nessan Bermingham, Ph.D., Founder and Chief Executive Officer,
Intellia Therapeutics. “We value their comprehensive industry
knowledge and previous board experiences, which along with the
formation of the new Science & Technology Committee, will help
shape Intellia as we move forward on our path to the clinic. We
thank Carl Gordon for his partnership and OrbiMed’s support of
Intellia that enabled our achievements and successes thus far.”
Intellia’s Board of Directors, committees,
chairpersons and members include:
- Chair of the Board: Perry Karsen
- Board Members: Perry Karsen, Nessan Bermingham, Caroline Dorsa,
Jean-François Formela, John Leonard, Moncef Slaoui and Frank
Verwiel
- Audit Committee: Caroline Dorsa (Chair), Jean-François Formela,
and Frank Verwiel
- Compensation Committee: Jean-François Formela (Chair), Caroline
Dorsa, Perry Karsen, and Moncef Slaoui
- Nominating & Corporate Governance Committee: Perry Karsen
(Chair), Caroline Dorsa and Frank Verwiel
- Science & Technology Committee: Moncef Slaoui (Chair),
Jean-François Formela and John Leonard
About Intellia Therapeutics
Intellia Therapeutics is a leading genome editing
company, focused on the development of proprietary, potentially
curative therapeutics using the CRISPR/Cas9 system. Intellia
believes the CRISPR/Cas9 technology has the potential to transform
medicine by permanently editing disease-associated genes in the
human body with a single treatment course. Our combination of deep
scientific, technical and clinical development experience, along
with our leading intellectual property portfolio, puts us in a
unique position to unlock broad therapeutic applications of the
CRISPR/Cas9 technology and create a new class of therapeutic
products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at
intelliatx.com; Follow us on Twitter @intelliatweets.
Forward-Looking
Statements
This press release contains “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995. Any forward-looking statements in this press
release are based on management's current expectations of future
events and are subject to a number of risks and uncertainties that
could cause actual results to differ materially and adversely from
those set forth in or implied by such forward-looking statements.
For a discussion of risks and uncertainties, and other important
factors, any of which could cause our actual results to differ from
those contained in the forward-looking statements, see the section
entitled "Risk Factors" in our most recent quarterly report on Form
10-Q filed with the Securities and Exchange Commission, as well as
discussions of potential risks, uncertainties, and other important
factors in our other filings with the Securities and Exchange
Commission. All information in this press release is as of the date
of the release, and Intellia Therapeutics undertakes no duty to
update this information unless required by law.
Intellia Contacts:
Jennifer Mound Smoter
Senior Vice President, External Affairs & Communications
857-701-1071
jenn.smoter@intelliatx.com
Graeme Bell
Executive Vice President, Chief Financial Officer
857-701-1081
graeme.bell@intelliatx.com
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Jul 2023 to Jul 2024